Mirfentanil antagonizes morphine-induced suppression of splenic NK activity in mice

Immunopharmacology

Volumn 34, Issue 1, 1996, Pages 9-16

  Carr, Daniel J J ^a   Brockunier, Linda L ^b   Scott, Mace ^a   Bagley, Jerome R ^b   France, Charles P ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b Ohmeda Inc   (United States)

Author keywords

Analgesia; Immunomodulation; Mirfentanil; Morphine; Natural killer activity; Opioid

Indexed keywords

BETA FUNALTREXAMINE; MIRFENTANIL; MORPHINE; MU OPIATE RECEPTOR; NALOXONAZINE; NALTREXONE; NALTRINDOLE; NORBINALTORPHIMINE;

ANIMAL CELL; ARTICLE; FEMALE; IMMUNOMODULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030220817     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/0162-3109(95)00051-8     Document Type: Article

References (25)

1. Bagley, J.R., Wynn, R.L., Rudo, F.G., Doorley, B.M., Spencer, H.K., Spaulding, T., New 4-(heteroanilido)piperidines, structurally related to the pure opioid agonist fentanyl, with agonist and/or antagonist properties. J Med Chem 1989; 32: 663-671.
2. Baker, M.L., Brockunier, L.L., Bagley, J.R., France, C.P., Carr, D.J.J., The fentanyl-related 4-heteroanilido piperidine OHM3295 augments splenic NK activity and induces analgesia through opioid receptor pathways. J Pharmacol Exp Ther 1995; 274: 1285-1292.
3. Bass, W.B., Vander Brook M.J., A note on an improved method of analgetic evaluation. J Am Pharm Ass 1952; 41: 569-570.
4. Beilin, B., Martin, F.C., Shavit, Y., Gale, R.P., Liebeskind, J.C., Suppression of natural killer cell activity by high-dose narcotic-anesthesia in rats. Brain Behavior Immun 1989; 3: 129-137.
5. Carr, D.J.J., Baker, M.L., Holmes, C., Brockunier, L.L., Bagley, J.R., France, C.P., OHM3295: A fentanyl-related 4-heteroanilido piperidine with analgesic effects but not suppressive effects on splenic NK activity in mice. Int J Immunopharmacol 1994c; 16: 835-844.
6. Carr, D.J.J., France, C.P., Immune alterations in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 1993; 267: 9-15.
7. 2 opioid receptors are involved in morphine-induced suppression of splenocyte natural killer activity. J Pharmacol Exp Ther 1993; 264: 1179-1186.
8. Carr, D.J.J., Gerak, L.R., France, C.P., Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice. J Pharmacol Exp Ther 1994b; 269: 693-698.
9. Carr, D.J.J., Mayo, S., Gebhardt, B.M., Porter, J., Central α-adrenergic involvement in morphine-mediated suppression of splenic NK activity. J Neuroimmunol 1994a, 53: 53-63.
10. D'Amour, F.E., Smith, D.L., A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941; 72: 74-79.
11. France, C.P., Winger, G., Medzihradshy, F., Seggel, M.R., Rice, K.C., Woods, J.H., Mirfentanil: Pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J Pharmacol Exp Ther 1991; 258: 502-510.
12. France, C.P., DeCosta, B.R., Jacobson, A.E., Rice, K.C., Woods, J.H., Apparent affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone. J Pharmacol Exp Ther 1990; 252: 600-604.
13. Freier, D.O., Fuchs, B.A., A mechanism of action for morphine-induced immunosuppression: Corticosterone mediates morphine-induced suppression of natural killer cell activity. J Pharmacol Exp Ther 1994; 270: 1127-1133.
14. Hanks, G.W., Twycross, R.G., Bliss, J.M., Controlled release morphine tablets: a double-blind trial in patients with advanced cancer. Anaesthesia 1987; 42: 840-844.
15. Herberman, R.B., Ortaldo, J.R., Natural killer cells: their role in defenses against disease. Science 1981; 214: 24-30.
16. Mathews, P.M., Froelich, C.J., Sibbitt, W.L., Bankhurst, A.D., Enhancement of natural cytotoxicity by β-endorphin. J Immunol 1983; 130: 1658-1662.
17. Paul, D., Bodnar, R.J., Gistrak, M.A., Pasternack, G.W., Different μ receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur J Pharmacol 1989; 168: 307-314.
18. 2 opioid action. Life Sci 1991; 48: 2005-2011.
19. Portenoy, R.K., Southam, M.A., Gupta, S.K., Lapin, J., Layman, M., Inturrisi, C.E., Foley, K.M., Transdermal fentanyl for cancer patients. Anesthesiology 1993; 78: 36-43.
20. Porteghese, P.S., Sultana, M., Takemori, A.E., Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur J Pharmacol 1988; 146: 185-186.
21. Radulovic, J., Miljevic, C., Djergovic, D., Vujic, V., Antic, J., von Horsten, S., Jankovic, B.D., Opioid receptor-mediated suppression of humoral immune response in vivo and in vitro: involvement of κ opioid receptors. J Neuroimmunol 1995; 57: 55-62.
22. Takemori, A.E., Ho, B.Y., Naeseth, J.S., Portoghese, P.S., Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 1988; 246: 255-258.
23. Twycross, R.G., Morphine and diamorphine in the terminally ill patient. Acta Anaesth Scand 1982: 74S: 128-134.
24. Weber, R.J., Pert, A., The periaquaductal gray matter mediates opiate-induced immunosuppression. Science 1989; 245: 188-190.
25. Woods, J.H., Medzihradshy, F., Smith, C.B., Winger, G.D., France, C.P., Evaluation of new compounds for opioid activity. NIDA Research Monograph Series. 1990; 105: 682-724.